Key result
Warfarin therapy provides substantial benefits in preventing thrombosis and stroke, but carries a major risk of bleeding that requires constant review of patient circumstances.
The substantial benefits of warfarin for thrombosis and stroke prevention must be constantly weighed against its major risk of bleeding on an individual patient basis.
Individualized benefit-risk assessment remains essential for warfarin; leaves open refinement of contemporary bleeding prediction tools.
The benefits of warfarin therapy are substantial in the prevention of arterial and venous thrombosis, and in the primary and secondary prevention of stroke related to non-rheumatic atrial fibrillation. The major risk of warfarin is bleeding, which can cause significant morbidity or mortality. If the bleeding risk is high then alternatives to therapeutic doses of warfarin may be considered, although their efficacy may be suboptimal and may not eliminate the risk of bleeding. Constantly review the patient's circumstances in order to weigh up the benefits and harms of treatment with warfarin.
No takes yet. Share an insight, caveat, or question.
Marija Borosak (2004) conducted a review in Arterial and venous thrombosis, non-rheumatic atrial fibrillation. Warfarin was evaluated. Warfarin therapy provides substantial benefits in preventing thrombosis and stroke, but carries a major risk of bleeding that requires constant review of patient circumstances.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: